TheraRadar
← Back
Data updated: Jun 28, 2026

AKCEA THERAPS

Pharma
Pharmaceuticals Execution: Good

AKCEA THERAPS is a pharmaceutical company with 1 FDA-approved products.

2018
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

FDA Novel Drug Designations

(2018)
1 Novel 1 First-in-Class 1 Orphan 1 Priority Review 1 Fast Track
See 1 novel approval →
2018 TEGSEDI (INOTERSEN SODIUM) First-in-Class · Orphan · Priority Review · Fast Track

AKCEA THERAPS at a Glance

  • Fast trial execution (21 months median completion)

AKCEA THERAPS's Key Drugs

AKCEA THERAPS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

AKCEA THERAPS's Recent FDA Approvals

New NDA/BLA approvals for AKCEA THERAPS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

AKCEA THERAPS's Therapeutic Areas

Disease areas where AKCEA THERAPS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

AKCEA THERAPS Pipeline Snapshot

Active clinical trials for AKCEA THERAPS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 1/1 completed
  • • Speed: 21 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges